ASCO 2019: Immunotherapy before surgery for treating metastatic kidney cancer

The results of this open-label pilot study were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. The study investigated the use of neoadjuvant (before surgery) immunotherapy in patients with metastatic renal cell carcinoma (RCC). One hundred and five patients with metastatic RCC were randomised to receive […]

read more

ASCO 2019: Analysis of CARMENA trial results using IMDC risk groups

The results from CARMENA, a randomised phase III clinical trial to assess the importance of surgery to remove the kidney (nephrectomy) in people with metastatic kidney cancer, have been re-analysed and were presented at the 2019 American Society of Clinical Oncology (ACSO) annual meeting in Chicago this week. The original results showed that many people with […]

read more

ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an […]

read more

ASCO GU 2019: Patient perspectives on cytoreductive nephrectomy after CARMENA

The following survey assessed patient views related to cytoreductive nephrectomy following publication of the results of the CARMENA trial, and were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The survey found that overall survival should not be overestimated as the most important aim […]

read more

ASCO GU 2019: Questions and lessons moving forward from CARMENA: A surgeon’s perspective

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from surgeon Dr Paul Russo, Memorial Sloan Kettering Cancer […]

read more

Surgery may not be the most appropriate frontline treatment for metastatic kidney cancer

Results of the phase 3 SURTIME trial comparing pretreatment with sunitinib before nephrectomy, with immediate nephrectomy followed by sunitinib treatment were published in JAMA Oncology recently. The findings suggest that pretreating metastatic renal cell carcinoma (RCC) patients with sunitinib before surgery may lead to better or at least similar outcomes for patients compared to immediate nephrectomy. Although […]

read more

ESOU 2019: Cytoreductive nephrectomy: Current recommendations

This review paper was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. Results from the CARMENA study were reviewed and recommendations made for cytoreductive nephrectomy for people with advanced renal cell carcinoma (RCC). CARMENA is a randomised clinical trial comparing patients who had […]

read more

Pros and cons of lymph node dissection at the time of nephrectomy

The following two presentations were given at the Canadian Uro-oncology Summit in Toronto last week on the pros and cons of removing lymph nodes during nephrectomy for renal cell carcinoma (RCC). In summary, lymph node dissection may be curative in patients with non-metastatic RCC, and may improve the patient’s response to systemic treatment in patients […]

read more

Deferred cytoreductive nephrectomy in kidney cancer fails to improve progression-free survival

Results from the phase 3 CARMENA study, published in the journal JAMA Oncology, found that pretreatment of renal cell carcinoma (RCC) patients with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week progression-free survival rates compared with immediate nephrectomy followed by sunitinib in these patients. However, patients who received sunitinib followed by deferred cytoreductive […]

read more

Highlights from video expert opinion on kidney cancer from ASCO 2018

The following video clips are useful highlights from video interviews with renal cell carcinoma (RCC) experts from the American Society of Clinical Oncology (ASCO) 2018 annual meeting in Chicago in June 2018. These video interviews were produced by PracticeUpdate. ASCO 2018: Critical practice impacting trials in GU oncology ASCO 2018: An overview of novel immunotherapy […]

read more
Showing 1 to 10 of 17 results
  TOP